VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KYMR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KYMRKymera Therapeutics, Inc.
$121.13$10.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksKYMRFinancials

Kymera Therapeutics, Inc. (KYMR) Income Statement

8Y historyFree accessUpdated daily

Reported revenue is lumpy and gross margin figures lack structural meaning, while R&D-driven operating losses of -$147.2M in 2026Q3 show costs outpacing any revenue offset.

Income StatementBalance SheetCash FlowRatios

KYMR Income Statement

Annual statement

KYMR Income Statement

Kymera Therapeutics, Inc. (KYMR) annual income statement — 8-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Sales/Revenue102.22M39.2M47.07M78.59M46.83M72.83M34.03M2.93M0
Revenue Growth %133.74%-16.72%-40.11%67.84%-35.71%114%1059.99%--
Cost of Goods Sold-76.18M000000825K205K
COGS % of Revenue-------28.12%-
Gross Profit178.4M39.2M47.07M78.59M46.83M72.83M34.03M2.11M-205K
Gross Margin %174.52%100%100%100%100%100%100%71.88%-
Gross Profit Growth %--16.72%-40.11%67.84%-35.71%114%1513.75%1128.78%-
Operating Expenses583.29M388.6M308.71M244.12M208.08M173.36M80.34M45.14M21.45M
OpEx % of Revenue-991.33%655.82%310.62%444.37%238.03%236.05%1538.48%-
Selling, General & Admin77.15M68.2M63.53M55.04M43.83M36.34M18.23M7.98M3.77M
SG&A % of Revenue-173.98%134.97%70.03%93.61%49.9%53.57%272.02%-
Research & Development430.01M316.6M240.25M189.08M164.25M137.02M62.1M37.16M17.68M
R&D % of Revenue-807.65%510.38%240.59%350.76%188.13%182.48%1266.46%-
Other Operating Expenses1000K3.8M4.92M000000
Operating Income-404.89M-349.4M-261.63M-165.53M-161.26M-100.53M-46.3M-42.2M-21.45M
Operating Margin %-396.08%-891.33%-555.82%-210.62%-344.37%-138.03%-136.05%-1438.48%-
Operating Income Growth %--33.54%-58.06%-2.65%-60.41%-117.11%-9.71%-96.75%-
EBITDA-396.78M-341.09M-254.26M-161.97M-158.28M-98.13M-44.54M-41.38M-21.25M
EBITDA Margin %-388.15%-870.12%-540.16%-206.08%-338.02%-134.74%-130.87%-1410.36%-
EBITDA Growth %-22.47%-34.15%-56.99%-2.33%-61.29%-120.32%-7.64%-94.77%-
D&A (Non-Cash Add-back)8.11M8.31M7.37M3.56M2.98M2.4M1.76M825K205K
EBIT-349.42M-311.37M-223.61M-146.77M-154.63M-100.04M-45.48M-41.2M-21.45M
Net Interest Income55.19M37.78M37.78M18.57M6.45M313K711K959K0
Interest Income55.47M38.03M38.03M18.76M6.62M488K826K1M0
Interest Expense273K249K249K196K176K175K115K46K16K
Other Income/Expense55.19M37.78M37.78M18.57M6.45M313K711K959K-16K
Pretax Income-349.7M-311.62M-223.86M-146.96M-154.81M-100.22M-45.59M-41.25M-21.47M
Pretax Margin %-342.09%-794.96%-475.57%-186.99%-330.6%-137.6%-133.96%-1405.79%-
Income Tax0000000043.86K
Effective Tax Rate %0%0%0%0%0%0%0%0%-0.2%
Net Income-349.47M-311.4M-223.86M-146.96M-154.81M-100.22M-45.59M-41.29M-21.47M
Net Margin %-341.87%-794.39%-475.57%-186.99%-330.6%-137.6%-133.96%-1407.36%-
Net Income Growth %-18.42%-39.11%-52.32%5.07%-54.47%-119.81%-10.42%-92.35%-
Net Income (Continuing)-349.7M-311.62M-223.86M-146.96M-154.81M-100.22M-45.59M-41.25M-21.47M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)-3.49-3.69-2.98-2.52-2.87-2.09-0.99-0.93-0.48
EPS Growth %-1.11%-23.83%-18.25%12.2%-37.32%-111.11%-6.45%-93.75%-
EPS (Basic)--3.69-2.98-2.52-2.87-2.09-0.99-0.93-0.48
Diluted Shares Outstanding100.1M84.39M75.04M58.37M53.93M47.99M44.56M44.53M44.53M
Basic Shares Outstanding100.1M84.39M75.04M58.37M53.93M47.99M44.56M44.53M44.53M
Dividend Payout Ratio---------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Sustained operating losses persist

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Lumpy Revenue Masks Persistent Losses

Based on reported figures, KYMR's quarterly revenue swung from $2.8M in 2025Q3 to $65.0M in 2026Q2, a pattern that suggests collaboration or milestone recognition rather than recurring product sales and warrants further investigation.

The revenue series is highly irregular, with several quarters near zero and a single $65.0M quarter in 2026Q2, which implies revenue is driven by lumpy licensing or collaboration events rather than steady commercial demand. Because operating expenses remained between roughly $100M and $147M per quarter throughout the period, even the strongest revenue quarter did not produce a sustained operating profit. Investors should monitor whether future revenue reflects repeatable partnership income or one-time recognition.

Gross Margin Figures Lack Structural Meaning

As reported in financial statements, KYMR's gross margin oscillates between roughly -26% and 100% with no COGS in most periods, so the metric appears to reflect collaboration accounting rather than product unit economics.

With cost of goods sold reported as zero in most quarters and negative in others, gross margin does not behave as a conventional cost-of-sales measure for this business. The more informative signal is operating margin, which remained deeply negative across all ten quarters, including -198.5% in 2024Q2 and -116.3% in 2026Q2. Analysts should treat gross margin as unreliable for valuation and focus on the operating expense base relative to collaboration revenue.

R&D Spending Drives the Cost Base

According to reported SEC filings, KYMR's R&D expense rose from $59.2M in 2024Q2 to $128.5M in 2026Q3, comprising the overwhelming majority of its operating cost structure and signaling sustained clinical investment.

R&D accounts for the large majority of total spending, while SG&A has stayed comparatively flat between roughly $15M and $21M per quarter, indicating disciplined general and administrative costs relative to research intensity. The more than doubling of R&D over the period suggests management is prioritizing pipeline advancement, which may be appropriate for a clinical-stage biotech but raises the funding requirement implied by the current loss rate. Stock-based compensation of roughly $14M to $19M per quarter is also a meaningful portion of operating expense.

Operating Losses Widen Despite Revenue Gains

Based on KYMR's reported figures, operating loss expanded from -$50.9M in 2024Q2 to -$147.2M in 2026Q3, indicating that cost growth has outpaced any revenue-driven offset rather than showing operating leverage.

Operating income has deteriorated as R&D expansion outweighed revenue growth, meaning the business is not exhibiting positive operating leverage at current revenue levels. Even when revenue reached $65.0M in 2026Q2, the operating loss remained at -$75.6M, which suggests the breakeven revenue level sits well above recent collaboration income. This pattern warrants further investigation into the timing and magnitude of future milestone receipts relative to planned spending.

Bear Case Centers on Cash Burn Duration

The strongest challenge to KYMR's income statement is that quarterly net losses of $60M to $130M appear unsustainable without recurring revenue, potentially pressuring future financing terms.

Short-sellers would likely emphasize that the company has not reported a profitable quarter in the ten-quarter window, and that revenue spikes do not offset a cost base that has grown toward $147M per quarter. Dilution is a plausible inference given EPS of -$1.32 in 2026Q3 and the loss scale, though the provided data does not disclose cash balances or financing arrangements, so this conclusion remains an inference requiring further investigation. The bullish counter is that R&D investment may be building a pipeline with asset value not captured in current income figures.

KYMR — Frequently Asked Questions

Quick answers to the most common questions about buying KYMR stock.

What was Kymera Therapeutics, Inc.'s (KYMR) revenue in 2025?

For fiscal year 2025, Kymera Therapeutics, Inc. (KYMR) reported total revenue of $39.2M.

Is Kymera Therapeutics, Inc. (KYMR) profitable?

Kymera Therapeutics, Inc. (KYMR) reported a net loss of $311.4M for the fiscal year ending 2025.

What is Kymera Therapeutics, Inc.'s operating profit margin?

Kymera Therapeutics, Inc. (KYMR) reported an operating income of $-349.4M, resulting in an operating profit margin of -891.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Kymera Therapeutics, Inc.'s gross profit and gross margin?

Kymera Therapeutics, Inc. (KYMR) generated $39.2M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.